Enovis (NYSE:ENOV) Insider Oliver Engert Acquires 1,000 Shares

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was bought at an average price of $23.00 per share, for a total transaction of $23,000.00. Following the completion of the transaction, the insider directly owned 50,640 shares in the company, valued at approximately $1,164,720. The trade was a 2.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average price of $22.22 per share, for a total transaction of $22,220.00.
• On Friday, March 13th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.74 per share, with a total value of $23,740.00.

Enovis Stock Performance

Shares of ENOV stock traded down $0.76 during mid-day trading on Thursday, reaching $21.21. The stock had a trading volume of 1,502,415 shares, compared to its average volume of 1,011,992. The firm’s 50 day simple moving average is $24.07 and its 200 day simple moving average is $24.63. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis Corporation has a one year low of $20.55 and a one year high of $36.82. The firm has a market cap of $1.22 billion, a PE ratio of 6.50 and a beta of 1.38.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter last year, the company earned $0.81 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on ENOV. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Wells Fargo & Company cut their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Needham & Company LLC raised their price target on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average price target of $44.50.

Hedge Funds Weigh In On Enovis

A number of institutional investors have recently modified their holdings of ENOV. Vanguard Group Inc. raised its holdings in Enovis by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after purchasing an additional 51,201 shares during the last quarter. Rubric Capital Management LP bought a new stake in Enovis during the 3rd quarter worth about $83,435,000. Paradigm Capital Management Inc. NY raised its holdings in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Finally, River Road Asset Management LLC raised its holdings in Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after purchasing an additional 46,289 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.